Collaboration Combines Prime Medicine's Precise, Multiplex Gene Editing Capabilities with Bristol Myers Squibb's Broad Expertise in Development and Commercialization of Novel Cell Therapies
Prime Medicine to Receive $110 Million Upfront, with Potential for More Than $3.5 Billion in Milestones, Including $1.4 Billion in Development Milestones and More Than $2.1 Billion in Commercialization Milestones
CAMBRIDGE, Mass., Sept. 30, 2024 (GLOBE NEWSWIRE) -- Prime Medicine, Inc. (Nasdaq: PRME) today announced a strategic research collaboration and license agreement with Bristol Myers Squibb (NYSE: BMY) to develop reagents for the next generation of ex vivo T-cell therapies. Under the terms of the agreement, Prime Medicine will design optimized Prime Editor reagents for a select number of targets, including reagents that use its Prime Assisted Site-Specific Integrase Gene Editing (PASSIGE) technology. Bristol Myers Squibb will be responsible for development, manufacturing and commercialization of the next generation cell therapies, with support from Prime Medicine in gene editing strategy and reagent development.
"We are excited to collaborate with Bristol Myers Squibb, a global leader in cell therapy for hematology, immunology, and oncology. Through this effort, we will apply our Prime Editing technology beyond the rare genetic diseases in our internal pipeline, potentially unlocking opportunities in areas of high unmet needs in immunological diseases and cancer," said Keith Gottesdiener, M.D., President and Chief Executive Officer of Prime Medicine. "We are particularly excited that efforts under this collaboration will leverage our PASSIGE technology, that we believe will advance our one-step, non-viral, multi-kilobase-size gene editing approach into the clinic. There is tremendous opportunity for PASSIGE and Prime Editing to revolutionize the field of cell therapy, and we look forward to expanding our reach over time through both internal and partnered efforts."
Prime Medicine's PASSIGE technology combines Prime Editing with an integrase or other site-specific recombinase to introduce large gene-sized cargo into the genome for stable cargo expression. PASSIGE is delivered through an entirely non-viral manufacturing process without introducing double-stranded DNA breaks or off-target edits and may enable more precise and effective genetic modification.
"We are excited to enter this agreement with Prime Medicine as we continue to explore and invest in next generation approaches, including gene editing technologies, that may help unlock the full potential of cell therapy," said Teri Foy, Senior Vice President of Cancer Immunology and Cell Therapy Therapeutic Research Center at Bristol Myers Squibb. "Integrating Prime Medicine's technologies with our internal capabilities has the potential to open new avenues for innovation and we look forward to collaborating with them as we continue to bring the promise of cell therapy to immunology and oncology."
Under the terms of the agreement, Prime Medicine will receive a $55 million upfront payment and a $55 million equity investment from Bristol Myers Squibb. Prime Medicine is also eligible to receive more than $3.5 billion in milestones, including up to $1.4 billion in development milestones and more than $2.1 billion in commercialization milestones, along with royalties on net sales.
About Prime Medicine
Prime Medicine is a leading biotechnology company dedicated to creating and delivering the next generation of gene editing therapies to patients. The Company is deploying its proprietary Prime Editing platform, a versatile, precise and efficient gene editing technology, to develop a new class of differentiated one-time curative genetic therapies. Designed to make only the right edit at the right position within a gene while minimizing unwanted DNA modifications, Prime Editors have the potential to repair almost all types of genetic mutations and work in many different tissues, organs and cell types. Taken together, Prime Editing's versatile gene editing capabilities could unlock opportunities across thousands of potential indications.
Prime Medicine is currently progressing a diversified portfolio of investigational therapeutic programs organized around our core areas of focus: hematology, immunology and oncology, liver and lung. Across each core area, Prime Medicine is focused initially on a set of high value programs, each targeting a disease with well-understood biology and a clearly defined clinical development and regulatory path, and each expected to provide the foundation for expansion into additional opportunities. Over time, the Company intends to maximize Prime Editing's broad and versatile therapeutic potential, as well as the modularity of the Prime Editing platform, to rapidly and efficiently expand beyond the diseases in its current pipeline, potentially including additional genetic diseases, immunological diseases, cancers, infectious diseases, and targeting genetic risk factors in common diseases, which collectively impact millions of people. For more information, please visit .
2024 Prime Medicine, Inc. All rights reserved. PRIME MEDICINE, the Prime Medicine logos, and PASSIGE are trademarks of Prime Medicine, Inc. All other trademarks referred to herein are the property of their respective owners.
合作将Prime Medicine的精准、多重基因编辑能力与百时美施贵宝在新型电芯治疗开发和商业化方面的广泛专业知识相结合
Prime Medicine将收到1.1亿美元的预付款,可能获得超过35亿美元的里程碑奖金,其中包括14亿美元的开发里程碑和超过21亿美元的商业化里程碑
马萨诸塞州剑桥,2024年9月30日(环球新闻社)-- Prime Medicine, Inc.(纳斯达克:PRME)今天宣布与百时美施贵宝(纽交所:BMY)达成战略性研究合作及许可协议,共同开发下一代体外t细胞疗法试剂。根据协议条款,Prime Medicine将为一些特定目标设计优化的Prime Editor试剂,包括利用其Prime辅助位点特异性整合酶基因编辑(PASSIGE)技术的试剂。百时美施贵宝将负责下一代细胞疗法的开发、制造和商业化,Prime Medicine将在基因编辑策略和试剂开发方面提供支持。
“我们很高兴与百时美施贵宝合作,后者是血液学、免疫学和肿瘤学领域的全球电芯治疗领导者。通过这一努力,我们将把我们的Prime编辑技术应用于我们内部管线中罕见的遗传疾病之外的领域,可能在免疫性疾病和癌症等高需求领域开启机会,”Prime Medicine首席执行官Keith Gottesdiener博士说道,“我们特别激动的是,这次合作中的努力将利用我们认为将把我们的一步、非病毒、多千碱基长度基因编辑方法推进到临床的PASSIGE技术。PASSIGE和Prime编辑有着巨大的机遇可以颠覆电芯治疗领域,并期待通过内部和合作努力逐渐扩展我们的影响力。”
Prime Medicine的PASSIGE技术结合了Prime Editing与整合酶或其他特异位点重组酶,将大型基因大小的载体引入基因组以实现稳定的载体表达。PASSIGE通过完全非病毒制造过程进行传递,不引入双链DNA断裂或非靶向编辑,可能使基因修饰更精准有效。
“我们很高兴与Prime Medicine达成协议,继续探索和投资下一代方法,包括基因编辑技术,这有助于释放细胞治疗的全部潜力,”百时美施贵宝癌症免疫学和细胞治疗治疗研究中心高级副总裁特里·福伊表示。“将Prime Medicine的技术与我们内部能力相结合,有可能开辟创新的新途径,我们期待与他们合作,继续为免疫学和肿瘤学带来细胞治疗的承诺。”
根据协议条款,Prime Medicine将获得百时美施贵宝的5500万美元的预付款和5500万美元的股权投资。Prime Medicine还有资格获得超过35亿美元的里程碑,包括高达14亿美元的开发里程碑和超过21亿美元的商业化里程碑,以及净销售收入的版税。
关于Prime Medicine
Prime Medicine是一家领先的生物技术公司,致力于为患者创造和提供下一代基因编辑治疗方案。公司正在部署其专有的Prime Editing平台,这是一种多用途、精确和高效的基因编辑技术,旨在开发一种全新的差异化一次性治愈遗传性疾病的基因治疗方案。设计的目的是仅在基因内的正确位置进行编辑,并最小限度地减少不需要的DNA修饰,Prime Editors 的潜力可以修复几乎所有类型的基因突变,并能在许多不同的组织、器官和细胞类型中发挥作用。综合来看,Prime Editing的多功能基因编辑功能可以解锁成千上万种潜在的适应症。
Prime Medicine目前正在推进一个围绕血液学、免疫学和肿瘤学、肝脏和肺部等核心领域组织的多样化疗法项目组合。在每个核心领域中,Prime Medicine最初专注于一组价值高的项目,每个项目都针对一个具有良好生物学理解和定义明确的临床开发和监管路径的疾病,预计为扩大进入其他机会奠定基础。随着时间的推移,公司打算最大限度地发挥Prime Editing广泛和多功能的治疗潜力,以及Prime Editing平台的模块化性,迅速高效地扩展到当前管道中的疾病之外,潜在包括额外的遗传疾病、免疫疾病、癌症、传染病,并针对常见疾病的遗传风险因素,这些疾病共影响数百万人。欲了解更多信息,请访问网站。
2024 Prime Medicine,Inc保留所有权利。PRIME MEDICINE、Prime Medicine标志和PASSIGE是Prime Medicine,Inc的商标。本公告所述其他任何商标均为其各自所有者的财产。